- Previous Close
8.46 - Open
8.58 - Bid 6.05 x 200
- Ask 8.02 x 100
- Day's Range
7.99 - 8.58 - 52 Week Range
7.99 - 18.75 - Volume
164,979 - Avg. Volume
671,404 - Market Cap (intraday)
292.18M - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
-- - EPS (TTM)
-2.96 - Earnings Date Nov 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.50
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
www.iteostherapeutics.comRecent News: ITOS
View More
Performance Overview: ITOS
Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ITOS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ITOS
View MoreValuation Measures
Market Cap
308.97M
Enterprise Value
-256.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.89
Price/Book (mrq)
0.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-13.04%
Return on Equity (ttm)
-19.72%
Revenue (ttm)
35M
Net Income Avi to Common (ttm)
-121.25M
Diluted EPS (ttm)
-2.96
Balance Sheet and Cash Flow
Total Cash (mrq)
488.71M
Total Debt/Equity (mrq)
0.88%
Levered Free Cash Flow (ttm)
-90.69M
Research Analysis: ITOS
View MoreCompany Insights: ITOS
ITOS does not have Company Insights
Research Reports: ITOS
View MoreWhat does Argus have to say about ITOS?
ITEOS THERAPEUTICS INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $8.00
ITEOS THERAPEUTICS INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $9.00
ITEOS THERAPEUTICS INC has an Investment Rating of SELL; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ITOS?
ITEOS THERAPEUTICS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target